Skip to main content
Top
Published in: World Journal of Surgery 5/2006

01-05-2006

Extent of Disease at Presentation and Outcome for Adrenocortical Carcinoma: Have We Made Progress?

Authors: Electron Kebebew, MD, Emily Reiff, BS, Quan-Yang Duh, MD, Orlo H. Clark, MD, Alex McMillan, PhD

Published in: World Journal of Surgery | Issue 5/2006

Login to get access

Abstract

Background

Adrenocortical carcinoma (ACC), a rare and aggressive malignancy, accounts for up to14% of adrenal incidentalomas. The only chance of cure for ACC is diagnosis at an early stage; therefore, a main indication for adrenalectomy in patients with adrenal incidentaloma has been the potential risk of ACC. Recent studies suggest that this has led to earlier stage of ACC at diagnosis, more curative operations, and better survival.

Methods

We analyzed data on ACC from The National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database. Four equal time quartiles (1973–1979, 1980–1986, 1987–1993, and 1994–2000) were compared for changes in demographics, pathology, treatment, and cause-specific mortality.

Results

The average age was 51.2 years (range: 1–97), and 45.9% of patients were men. The average tumor size was 12 cm (range: 2–36 cm), and only 4.2% were ≤ 6 cm. Most (88%) patients had surgical resection of their tumor, and external beam radiotherapy was used in only 12% of patients. Between the time quartiles compared (as well as annually), there was no significant difference at presentation in age at diagnosis, sex, race/ethnicity, tumor size, tumor grade, the frequency of distant metastasis, and overall TNM stage. Low tumor grade, lower stage of ACC, later time quartile, and surgical resection were associated with a lower cause-specific mortality by univariate analysis (P ≤ 0.002) and by multivariate analysis (P ≤ 0.031).

Conclusions

Although adrenal incidentalomas have become a common indication for adrenalectomy, this has not resulted in patients with ACC being diagnosed earlier or treated at a lower stage of disease at the national level. The most important predictors of survival in these patients are tumor grade, tumor stage, and surgical resection.
Literature
1.
go back to reference Sidhu S, Sywak M, Robinson B, et al. Adrenocortical cancer: recent clinical and molecular advances. Curr Opin Oncol 2004;16:13–18CrossRefPubMed Sidhu S, Sywak M, Robinson B, et al. Adrenocortical cancer: recent clinical and molecular advances. Curr Opin Oncol 2004;16:13–18CrossRefPubMed
2.
go back to reference Allolio B, Hahner S, Weismann D, et al. Management of adrenocortical carcinoma. Clin Endocrinol (Oxf) 2004;60:273–287CrossRef Allolio B, Hahner S, Weismann D, et al. Management of adrenocortical carcinoma. Clin Endocrinol (Oxf) 2004;60:273–287CrossRef
3.
go back to reference Icard P, Goudet P, Charpenay C, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons Study Group. World J Surg 2001;25:891–897CrossRefPubMed Icard P, Goudet P, Charpenay C, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons Study Group. World J Surg 2001;25:891–897CrossRefPubMed
4.
go back to reference Kendrick ML, Lloyd R, Erickson L, et al. Adrenocortical carcinoma: surgical progress or status quo? Arch Surg 2001;136:543–549CrossRefPubMed Kendrick ML, Lloyd R, Erickson L, et al. Adrenocortical carcinoma: surgical progress or status quo? Arch Surg 2001;136:543–549CrossRefPubMed
5.
go back to reference Mansmann G, Lau J, Balk E, et al. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev 2004;25:309–340CrossRefPubMed Mansmann G, Lau J, Balk E, et al. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev 2004;25:309–340CrossRefPubMed
6.
go back to reference Chen DY, Sosa RE, Scherr DS. Treatment of adrenocortical carcinoma: contemporary outcomes. Curr Urol Rep 2004;5:65–72PubMed Chen DY, Sosa RE, Scherr DS. Treatment of adrenocortical carcinoma: contemporary outcomes. Curr Urol Rep 2004;5:65–72PubMed
7.
go back to reference Sturgeon C, Kebebew E. Laparoscopic adrenalectomy for malignancy. Surg Clin North Am 2004;84:755–774CrossRefPubMed Sturgeon C, Kebebew E. Laparoscopic adrenalectomy for malignancy. Surg Clin North Am 2004;84:755–774CrossRefPubMed
8.
go back to reference Warren JL, Harlan LC. Can cancer registry data be used to study cancer treatment? Med Care 2003;41:1003–1005CrossRefPubMed Warren JL, Harlan LC. Can cancer registry data be used to study cancer treatment? Med Care 2003;41:1003–1005CrossRefPubMed
9.
go back to reference Reynolds T. Report examines association between cancer and socioeconomic status. J Natl Cancer Inst 2003;95:1431–1433PubMed Reynolds T. Report examines association between cancer and socioeconomic status. J Natl Cancer Inst 2003;95:1431–1433PubMed
10.
go back to reference Kadan-Lottick NS, Ness KK, Bhatia S, Gurney JG, et al. Survival variability by race and ethnicity in childhood acute lymphoblastic leukemia. J Am Med Assoc 2003;290:2008–2014CrossRef Kadan-Lottick NS, Ness KK, Bhatia S, Gurney JG, et al. Survival variability by race and ethnicity in childhood acute lymphoblastic leukemia. J Am Med Assoc 2003;290:2008–2014CrossRef
11.
go back to reference Gatta G, Ciccolallo L, Capocaccia R, et al. Differences in colorectal cancer survival between European and US populations: the importance of sub-site and morphology. Eur J Cancer 2003;39:2214–2222CrossRefPubMed Gatta G, Ciccolallo L, Capocaccia R, et al. Differences in colorectal cancer survival between European and US populations: the importance of sub-site and morphology. Eur J Cancer 2003;39:2214–2222CrossRefPubMed
14.
go back to reference Tauchmanova L, Colao A, Marzano LA, et al. Andrenocortical carcinomas: twelve-year prospective experience. World J Surg 2004;28:896–903CrossRefPubMed Tauchmanova L, Colao A, Marzano LA, et al. Andrenocortical carcinomas: twelve-year prospective experience. World J Surg 2004;28:896–903CrossRefPubMed
15.
go back to reference Wajchenberg BL, Albergaria Pereira MA, et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer 2000;88:711–736CrossRefPubMed Wajchenberg BL, Albergaria Pereira MA, et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer 2000;88:711–736CrossRefPubMed
16.
go back to reference Wooten MD, King DK. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 1993;72:3145–3155PubMed Wooten MD, King DK. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 1993;72:3145–3155PubMed
17.
go back to reference Stojadinovic A, Ghossein RA, Hoos A, et al. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol 2002;20:941–950CrossRefPubMed Stojadinovic A, Ghossein RA, Hoos A, et al. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol 2002;20:941–950CrossRefPubMed
18.
go back to reference Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol 1999;6:719–726CrossRefPubMed Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol 1999;6:719–726CrossRefPubMed
19.
go back to reference Tritos NA, Cushing GW, Heatley G, et al. Clinical features and prognostic factors associated with adrenocortical carcinoma: Lahey Clinic Medical Center experience. Am Surg 2000;66:73–79PubMed Tritos NA, Cushing GW, Heatley G, et al. Clinical features and prognostic factors associated with adrenocortical carcinoma: Lahey Clinic Medical Center experience. Am Surg 2000;66:73–79PubMed
20.
go back to reference Harrison LE, Gaudin PB, Brennan MF. Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection. Arch Surg 1999;134:181–185CrossRefPubMed Harrison LE, Gaudin PB, Brennan MF. Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection. Arch Surg 1999;134:181–185CrossRefPubMed
21.
go back to reference Haak HR, Cornelisse CJ, Hermans J, et al. Nuclear DNA content and morphological characteristics in the prognosis of adrenocortical carcinoma. Br J Cancer 1993;68:151–155PubMed Haak HR, Cornelisse CJ, Hermans J, et al. Nuclear DNA content and morphological characteristics in the prognosis of adrenocortical carcinoma. Br J Cancer 1993;68:151–155PubMed
22.
go back to reference de Fraipont F, El Atifi M, Cherradi N, et al. Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab 2005;90:1819–1829CrossRefPubMed de Fraipont F, El Atifi M, Cherradi N, et al. Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab 2005;90:1819–1829CrossRefPubMed
Metadata
Title
Extent of Disease at Presentation and Outcome for Adrenocortical Carcinoma: Have We Made Progress?
Authors
Electron Kebebew, MD
Emily Reiff, BS
Quan-Yang Duh, MD
Orlo H. Clark, MD
Alex McMillan, PhD
Publication date
01-05-2006
Publisher
Springer-Verlag
Published in
World Journal of Surgery / Issue 5/2006
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-005-0329-x

Other articles of this Issue 5/2006

World Journal of Surgery 5/2006 Go to the issue